EP658 Adjuvant locoregional chemo-irradiation followed by sequential chemotherapy for high risk endometrial cancer, single centre real-world experience

Autor: Wlw Yip, Csf Wong, Nsj Cheng

Publikováno v: ePoster.

Introduction/Background PORTEC-3 study has illustrated failure-free survival benefit in the subgroup of patients with stage III endometrial cancer. This study reports the toxicities and pattern of relapse for patients with high risk endometrial cance

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2ef93c7f80370945baea9006a9bd646f
https://doi.org/10.1136/ijgc-2019-esgo.713

Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.

Autor: Lee KCE; Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong., Mui WH; Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong., Chan W; Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong., Wong CSF; Department of Clinical Oncology, Tuen Mun Hospital, Tuen Mun, Hong Kong., Chu SKP; Department of Surgery, Tuen Mun Hospital, Tuen Mun, Hong Kong.

Publikováno v: Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2019 Aug; Vol. 2 (4), pp. e1170. Date of Electronic Publication: 2019 Mar 24.

Tracking the fate of adoptively transferred myeloid-derived suppressor cells in the primary breast tumor microenvironment.

Autor: Sceneay J; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia., Griessinger CM; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany., Hoffmann SHL; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany., Wen SW; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia., Wong CSF; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia., Krumeich S; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia., Kneilling M; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany.; Department of Dermatology, Eberhard Karls University Tübingen, Tübingen, Germany., Pichler BJ; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, Tübingen, Germany., Möller A; Tumor Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.; School of Medicine, University of Queensland, Brisbane, Australia.

Publikováno v: PloS one [PLoS One] 2018 Apr 20; Vol. 13 (4), pp. e0196040. Date of Electronic Publication: 2018 Apr 20 (Print Publication: 2018).

The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.

Autor: Kodack DP; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Askoxylakis V; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Ferraro GB; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Sheng Q; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Badeaux M; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Goel S; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Qi X; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Shankaraiah R; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Cao ZA; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Ramjiawan RR; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Bezwada D; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Patel B; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Song Y; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA., Costa C; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA., Naxerova K; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Wong CSF; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Kloepper J; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Das R; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Tam A; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Tanboon J; Department of Pathology, MGH and HMS, Boston, MA 02114, USA., Duda DG; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Miller CR; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27514, USA., Siegel MB; Department of Genetics, University of North Carolina, Chapel Hill, NC 27514, USA., Anders CK; Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA., Sanders M; Department of Pathology, Microbiology, and Immunology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA., Estrada MV; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA., Schlegel R; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Arteaga CL; Departments of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA., Brachtel E; Department of Pathology, MGH and HMS, Boston, MA 02114, USA., Huang A; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA., Fukumura D; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA., Engelman JA; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA. jain@steele.mgh.harvard.edu jeffrey.engelman@novartis.com., Jain RK; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA. jain@steele.mgh.harvard.edu jeffrey.engelman@novartis.com.

Publikováno v: Science translational medicine [Sci Transl Med] 2017 May 24; Vol. 9 (391).